Please assess the completion status of the following clinical trial:

Trial Title: Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heterozygote or homozygote of HLA-A\*02:01 allele~* Inoperable or recurrent pancreatic cancer with or without any prior therapy~* Difficult to continue the prior therapy due to treatment-related toxicities~* ECOG performance status 0-2~* Evaluable primary or metastatic lesion with RECIST v.1.0 criteria~* Clearance period from prior therapy more than 4 weeks~* Life expectancy more than 3 months~* Laboratory values as follows 2,000/μL\< WBC \<15,000/μL Platelet count \>100,000/μL AST \<150 IU/L ALT \<150 IU/L Total bilirubin \<3.0 mg/dl Serum creatinine \<3.0 mg/dl~Exclusion Criteria:~* Pregnancy (refusal or inability to use effective contraceptives)~* Breastfeeding~* Active or uncontrolled infection~* Systemic use of corticosteroids or immunosuppressants~* Uncontrollable brain metastasis and/or meningeal infiltration~* Unhealed external wound~* Possibilities of complicated paralytic ileus or interstitial pneumonitis~* Decision of not eligible determined by principal investigator or attending doctor

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Peptide vaccination (Type: EXPERIMENTAL): VEGFR1-derived HLA-A\*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m\^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.

Based on this trial design, predict the completion outcome and termination type (if applicable).